Symbols

SIBN

SI-BONE·NASDAQ

--(--)

SIBN fundamentals

SIBN Q4 2025 Earnings

SI-BONE (SIBN) released its earnings on Feb 23, 2026: revenue was 56.35M (YoY +15.00%), beat estimates; EPS was -0.04 (YoY +63.64%), beat estimates.

Revenue / YoY

56.35M

+15.00%

EPS / YoY

-0.04

+63.64%

Report date

Feb 23, 2026

SIBN Earnings Call Summary for Q4,2025

20% Revenue Growth: 2025 revenue reached $200.9 million, driven by 22% U.S. physician adoption and 38.8% international expansion.
Breakthrough Products: INTRA Ti launched in Q4, with a third BDD expected in late 2026. TORQ TNT adoption surged 50% Q4 YoY.
Strategic Expansion: Smith & Nephew partnership to accelerate trauma market penetration, targeting Level 1/2 centers.
Profitability Milestones: 9% Q4 adjusted EBITDA margin, first positive free cash flow, and $14 million annual EBITDA improvement.
2026 Outlook: 14-16% revenue growth, 78% gross margin, and H2-weighted growth from new products and reimbursement tailwinds.

Earnings

EPS

Revenue

Revenue & Expenses

SIBN has released its 2025 Q4 earnings report, with revenue of 56.35M, reflecting a YoY change of 14.99%, and net profit of -1.64M, showing a YoY change of 63.43%. The Sankey diagram below clearly presents SIBN's revenue sources and cost distribution.

Key Indicators

SI-BONE (SIBN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

SI-BONE (SIBN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

SI-BONE (SIBN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

SI-BONE (SIBN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown